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10 ABSTRACT: Two diﬀerent structures of zeolites, faujasite (FAU)
11 and Linde type A (LTA), were studied to investigate their suitability
12 for drug delivery systems (DDS). The zeolites in the sodium form
13 (NaY and NaA) were used as hosts for encapsulation of α-cyano-4-
14 hydroxycinnamic acid (CHC). CHC, an experimental anticancer
15 drug, was encapsulated in both zeolites by diﬀusion in liquid phase.
16 These new drug delivery systems, CHC@zeolite, were characterized
17 by spectroscopic techniques (FTIR, 1H NMR, 13C and 27Al solid-
18 state MAS NMR, and UV−vis), chemical analysis, powder X-ray
19 diﬀraction (XRD) and scanning electron microscopy (SEM). The
20 eﬀect of the zeolites and CHC@zeolite drug deliveries on HCT-15
21 human colon carcinoma cell line viability was evaluated. Both
22 zeolites alone revealed no toxicity to HCT-15 cancer cells. Importantly, CHC@zeolite exhibit an inhibition of cell viability up to
23 585-fold, when compared to the non-encapsulated drug. These results indicate the potential of the zeolites for drug loading and
24 delivery into cancer cells to induce cell death.
25 ■ INTRODUCTION
26 Several inorganic materials are being explored as drug carriers
27 opening new possibilities for biomedical applications.1 Due to
28 their biological properties and stability in biological environ-
29 ments, zeolites have been recently considered for medical
30 use.2,3 Zeolites are solid inorganic crystalline materials
31 comprised of silicon, aluminum, and oxygen in the three-
32 dimensional structure and the building blocks become arranged
33 in a periodic way to form channels and cages on a nano- and
34 subnanometer scale of strictly regular dimensions, named
35 micropores.4
36 There are numerous examples of biomedical applications of
37 zeolites reported in the literature including the enrichment and
38 identiﬁcation of low abundance peptides/proteins,5 the
39 immobilization of enzymes for biosensing,6 for processes in
40 magnetic resonance imaging,6−10 in wound treatment,11 and as
41 drug delivery systems (DDS).12−16 In DDS, the zeolitic
42 structures and drugs could be simultaneously administrated to
43 a patient without loss of the individual pharmacological eﬀect of
44 each product.17−20 However, relatively fewer studies have been
45 reported exploring the potential of zeolites as DDS for cancer
46 applications. The latest experimental studies, based on the
47 results obtained in various tumor cells and in tumor bearing
48 animals, have shown that zeolites can be successfully applied as
49 adjuvants in anticancer therapy.21 In this context, we have
50previously reported the preparation of a DDS based in zeolite Y
51with an anticancer drug and demonstrated its eﬃcacy against
52colorectal carcinoma (CRC) cells in vitro.22 CRC is the most
53common type of tumor in Western countries, being men
54slightly more often aﬀected.23 Treatment of CRC includes
55surgery, radiotherapy, and/or chemotherapy. However, the
56treatment design depends largely on the cancer stage. Despite
57the progress made with the introduction of new cytotoxic
58agents24−28 and medical practices, survival rates of patients with
59CRC changed little over the last 20 years,29 justifying the need
60for more eﬀective therapies and new drugs.
61α-Cyano-4-hydroxycinnamic acid (CHC) is a compound
62derived from cinnamic acid and is a competitive inhibitor of
63monocarboxylate transporter 1 (MCT1),30 a protein recently
64shown to be upregulated in colorectal and other cancers and
65thus a potential target for cancer therapy.31−33 Published data
66demonstrated the cytotoxic and cytostatic eﬀectiveness of
67CHC,34,35 both in vitro and in vivo.36,37 CHC used here in a
68model of colon carcinoma was chosen as a guest in two
69diﬀerent structures of zeolites for drug delivery. Due to their
70structural properties, zeolites have attracted much research
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71 attention for their potential application in the ﬁelds of
72 biotechnology, selective adsorption, heterogeneous catalysis,
73 polymer catalytic degradation, and functional materials.4,38−41
74 The faujasite framework of zeolite Y is based on sodalite
75 cages that are joined by oxygen bridges between the hexagonal
76 faces. Eight sodalite cages are linked together, forming a large
77 central cavity or supercage with a diameter of 1.18 nm. The
78 supercages share a 12-membered ring with an open diameter of
79 0.74 nm.42 However, zeolite A exhibits LTA (Linde Type A)
80 structure with small pores. The pore diameter is deﬁned by an
81 eight-member oxygen ring with an open diameter of 0.42 nm.
82 This leads into a larger cavity of minimum free diameter 1.14
83 nm. The cavity is surrounded by eight sodalite cages (truncated
84 octahedra), connected by their square faces in a cubic
85 structure.43−45
86 In this study, we present the results obtained with two
87 diﬀerent synthetic structures of zeolites, faujasite (FAU) and
88 Linde type A (LTA), and their suitability as drug delivery
89 systems (DDS) for the anticancer drug CHC. The zeolites in
90 sodium form (NaY and NaA) were used for encapsulation of
91 CHC as a guest by diﬀusion in the liquid phase in the void
92 space of the host zeolite porosity. The eﬀect of the CHC
93 concentration in both zeolites was studied. These new DDS
94 were characterized by diﬀerent methods (FTIR, 1H NMR, 13C
95 and 27Al solid-state MAS NMR, UV−vis, SEM, XRD, and
96 elemental analysis). The eﬀect of the zeolites and CHC@
97 zeolite DDS was evaluated on HCT-15 human colon carcinoma
98 cell viability.
99 ■ EXPERIMENTAL SECTION
100 Preparation and Characterization of DDS. The zeolitic
101 structures are commercially available; FAU zeolite in powder
102 form (CBV100) was obtained from Zeolyst International and
103 Linde type A zeolite from Sigma-Aldrich (European Commis-
104 sion, Institute for Reference Materials and Measurements,
105 BCR-705). Zeolite NaA was available in pellet form with clay
106 impurities and was transformed in powder before use. The
107 encapsulation of CHC (α-cyano-4-hydroxycinnamic acid,
108 Sigma-Aldrich) in zeolites was based on a previously established
109 procedure.20 Zeolites were dehydrated at 120 °C overnight,
110 prior to insertion of the drug, to avoid the presence of water
111 inside the pores, which renders the adsorption of the drug
112 molecules more diﬃcult. CHC encapsulation into the zeolites
113 was achieved as follows: 500 mg of each zeolite with diﬀerent
114 Si/Al atomic ratios, NaY (Si/Al ratio = 2.83) and NaA (Si/Al
115 ratio = 1.24) was reacted with a solution of 49.20 mg of CHC
116 (0.26 mmol) in acetone (15 mL, Merck analytical grade), as a
117 solvent. This mixture was carried out by stirring at room
118 temperature for 48 h. During this time, the original white color
119 of zeolites changed to the characteristic color of the CHC,
120 yellow, indicating that the drug species were eﬀectively
121 incorporated inside the host. This ﬁnding was also conﬁrmed
122 by the disappearance of the yellow color of the starting CHC
123 solution after 3 h in contact with the zeolite and the eﬃciency
124 of the encapsulation was screened by HPLC.
125 The mixture was ﬁltered and the yellow solid was dried in an
126 oven at 60 °C for 12 h. This temperature is enough to
127 evaporate the acetone solvent. Two other samples with
128 diﬀerent CHC concentrations, 98.40 mg of CHC (0.52
129 mmol) and 246.00 mg of CHC (1.30 mmol), were prepared
130 in both zeolites under the same experimental conditions. The
131 obtained DDS were denoted as CHC@zeoliten, where n
132 represents the CHC:zeolite ratio. The drug loading in the
133zeolites was determined by gravimetric analysis. In this
134technique, loading was obtained between the diﬀerence in
135weights of the powder starting zeolite and the DDS prepared by
136using an analytical balance (Precisa 40SM-200A ± 0.00001 g).
137In order to evaluate the solvent eﬀect, the zeolites were
138prepared with 15 mL of solvent, using the same experimental
139conditions as the CHC@zeolites samples.
140Characterization Methods. 13C cross-polarization/magic
141angle spinning nuclear magnetic resonance (13C CP/MAS
142NMR) and MAS 27Al spectra were recorded on a 9.4 T wide-
143bore (400 MHz, 1H Larmor frequency) Bruker Avance
144spectrometer. A 4 mm double-resonance MAS probe was
145employed at 100.6 (13C) and 104.2 MHz (27Al) Larmor
146frequencies. Samples were spun in ZrO2 rotors, using a
147spinning rate of 14 kHz. 13C CP/MAS NMR spectra were
148recorded with use of a ramp step (varying from 100% to 50% in
149amplitude using 100 points); contact time: 3.0 ms; 1H 90°
150excitation pulse: 2.5 μs; 1H and 13C radio frequency ﬁeld
151strengths for CP were set to 87 and 68 kHz, respectively;
152recycle delay: 5 s. TPPM-15 decoupling was employed during
153the signal acquisition, using a 4.75 μs pulse length for the basic
154TPPM pulse unit along the 1H channel, employing a 1H radio
155frequency ﬁeld strength of 100 kHz. For the 27Al MAS
156experiments, a 0.50 μs pulse length was applied, equivalent to a
157ﬂip angle of 10°. 13C chemical shifts are quoted in parts per
158million (ppm) from TMS and calibrated with respect to the
159external reference, glycine (CO, 176.03 ppm). All 27Al chemical
160shifts were referenced with respect to an aqueous solution of
161Al(NO3)3. All samples were kept in a sealed container and
162exposed to a saturated solution of K2SO4 (relative humidity of
16397%) for two weeks, prior to the acquisition of solid-state NMR
164data. This experimental protocol was necessary to guarantee the
165full hydration of the samples and therefore the reproducibility
166of the results. The quantitative analysis (Si, Al, and Na) was
167carried out by Inductively Coupled Plasma Atomic Emission
168Spectrometry (ICP-AES), using a Philips ICP PU 7000
169spectrometer. Elemental analyses for carbon, nitrogen, and
170hydrogen were carried out on LECO CHNS-932 equipment.
171Samples were combusted at 1000 °C for 3 min with helium
172used as the purge gas. 1H NMR spectra were obtained on a
173Varian Unity Plus spectrometer at an operating frequency of
174300 MHz, using the solvent peak as internal reference at 25 °C,
175chemical shifts of protons being given in ppm using δH Me4Si =
1760 ppm as reference. The electronic UV−visible absorption
177spectra of drug and residual solutions were collected in the
178range 600−200 nm in a Shimadzu UV/2501PC spectropho-
179tometer, using quartz cells at room temperature. Phase analysis
180was performed by XRD with a Philips PW1710 diﬀractometer.
181Scans were taken at room temperature in a 2θ range between
1825° and 60°, using Cu Kα radiation. Scanning electron
183micrographs (SEM) were collected on a LEICA Cambridge
184S360 scanning microscope equipped with an EDX system. To
185avoid surface charging, samples were coated with gold under
186vacuum prior to analysis, using a Fisons Instruments SC502
187sputter coater. The analysis was carried out by high
188performance liquid chromatography (HPLC JASCO 980-PU),
189using an isocratic pump and a double on line detection
190including an UV−vis detector and refractometer. Room
191temperature Fourier transform infrared (FTIR) spectra of the
192samples in KBr pellets (2 mg of sample was mixed in a mortar
193with 200 mg of KBr) were measured with a Bomem MB104
194spectrometer in the range 4000−500 cm−1 by averaging 20
195scans at a maximum resolution of 4 cm−1.
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196 Cell Culture Conditions. Human colon carcinoma-derived
197 cell line HCT-15 was kindly provided by Dr. Raquel Seruca,
198 (IPATIMUP, Porto, Portugal). HCT-15 colon carcinoma cells
199 were maintained in RPMI 1640 medium (Gibco), supple-
200 mented with 10% (v/v) fetal bovine serum (FBS) (Gibco,
201 Invitrogen, USA) and 1% (v/v) penicillin-streptomycin
202 solution (P/S) (Invitrogen, USA) and incubated at 37 °C in
203 a 5% CO2 humidiﬁed atmosphere. Cells were subcultured
204 approximately every three days and maintained in a log-phase
205 growth.
206 Cell Viability Assays. Cell viability was assessed using the
207 In Vitro Toxicology Assay Kit, Sulforhodamine B based (Sigma-
208 Aldrich, St. Louis, MO, USA). HCT-15 cells were seeded in 96-
209 well plates (5000 cells/100 μL/well) and incubated at 37 °C in
210 a 5% CO2 humidiﬁed atmosphere for 24 h. To assess the eﬀects
211 of the starting zeolites and the CHC@zeolite systems used
212 (NaA and NaY), cells were incubated with increasing
213 concentrations of the systems in culture medium. Controls
214 were performed with culture medium alone. After an
215 incubation period of 24 h, the spent media were removed
216 and the plate wells were washed with 1× Phosphate-buﬀered
217 solution, pH 7.4 (PBS). After a ﬁxation step with cold 10%
218 trichloroacetic acid (TCA), cells were stained with 0.4%
219 Sulforhodamine B and the incorporated dye was solubilized
220 with Sulforhodamine B solubilization solution (10 mM Tris).
221 Absorbance was monitored with a microplate reader at 570 nm
222 with a background absorbance of 655 nm. Cell viability was
223 determined as percentage of viability: (OD experiment/OD
224 control) × 100 (%). Results are presented as mean ± standard
225 deviation (SD) of three independent experiments, each in
226 triplicate. One-way ANOVA, followed by Dunnett post test was
227 used to perform cell viability assay statistical analysis. The
228 previous test and 50% growth inhibition (IC50) were
229 determined with Graphpad Prism 5 software. Values were
230 considered statistically signiﬁcant in all experiments when p <
231 0.05.
232 ■ RESULTS AND DISCUSSION
233 Preparation and Characterization of DDS. In the
234 present study, the anticancer drug CHC was chosen to test
235 the use of zeolite structures as DDSs. The approach for the
236 preparation of DDS was the adsorption of CHC as a guest in
237 liquid phase within the framework of the zeolite as a host. This
238 approach required that the drug diﬀused inward the space
239 available of the zeolite framework and the starting zeolites were
240 not cytotoxic to the HCT-15 cell line. In this cell line,
241 preliminary studies with NaY, NaMOR, NaA, and ZSM5 were
242 also carried out. NaY (Faujasite) and NaA structures (Linde
243 type A) showed to be nontoxic to the cells.
244Both zeolites have diﬀerent pore diameters, large pores for
245NaY (7.4 Å) and small pores for NaA (4.2 Å), which can
246determine the access of CHC into the structures. However, for
247CHC the length between the OH group from the aryl ring and
248the COOH is approximately 10.6 Å in the planar and linear
249molecule, and the aryl ring is 5.9 Å, suggesting that this drug
250could have some diﬃculty in diﬀusing into the NaA zeolite
251structure. The loading of CHC into the zeolites was determined
252 t1by gravimetric analysis. Table 1 shows the loading obtained for
253all prepared DDS.
254The residual drug content in solution after evaporation of the
255solvent is very low. In the case of NaY zeolite, around 85% of
256the CHC initially present has been retained inside this zeolite.
257However, for NaA, only 67−76% of the CHC was incorporated
258into the structure.
259To conﬁrm the integrity of the molecular structure of CHC
260after preparation of DDS, 1H NMR and UV−vis experiments
261were performed with the residual drug solid obtained after
262ﬁltration and pure CHC. The 1H NMR spectra of the samples
263were recorded at 300 MHz in CDCl3. The chemical shifts of
264protons observed for residual drug are δ 13.3 (s, COOH), 10.6
265(s, OH), 8.3 (s, CH), and 7.8 and 6.7 (2ddd, 4H from the
266aryl group). These chemical shifts of protons are in the same
267position as observed for the CHC pure molecule.46 In the UV−
268vis spectrum, the presence of residual drug was evidenced by
269the appearance of an intense band (λmax = 334 nm) in the same
270position of CHC in acetone (λmax = 337 nm).
46 These results
271show that the encapsulation process preserved the integrity of
272CHC.
273Preservation of the zeolite structures of the DDS was
274monitored by powder X-ray diﬀraction (XRD). The powder
275XRD diﬀraction patterns of the zeolites and encapsulated CHC
276were recorded at 2θ values between 5° and 60°. The parent
277zeolite Y sample is pure, while LTA is contaminated with a
278small amount of an unidentiﬁed phase displaying a main
279resonance at 26.6° 2θ probably due to the presence of clay in
280the pellet form. All samples exhibited XRD patterns similar to
281the patterns of the parent zeolites. No variation was observed in
282the characteristic peaks of zeolites after encapsulation of CHC,
283indicating that the frameworks did not undergo any signiﬁcant
284structural change during the CHC encapsulation process. The
285XRD pattern of DDS prepared with NaY presented over 85%
286of crystallinity, while for NaA the crystallinity was ca. 75%.
287The morphology of the DDS obtained after the encapsula-
288 f1tion was observed by SEM analysis. Figure 1 shows the parent
289zeolites and the DDS with lower concentration of CHC.
290The SEM micrographs of parent zeolites and the DDS
291indicate that no changes occur in the morphology and structure
292upon encapsulation of the drug. In panels a and c of Figure 1, it
293is clear from the micrographs of NaY and CHC@Y1:10 that the
294morphology of the zeolite does not change after encapsulation
295of the CHC. The SEM microphotographs of the parent NaY
296and the DDS are typical of a microporous crystalline
297aluminosilicate structure with regular small particles.47,48 The
298average of the particle diameter of the starting NaY was about
2990.4−1.0 μm and the DDS preserved the same diameter. The
300starting NaA (Figure 1b) and its DDS (Figure 1d), two types of
301particles with diﬀerent dimensions, can be observed: (i)
302aggregates of particles with a diameter of ∼2.6−5.0 μm and
303(ii) particles with a diameter of ∼0.3−1.0 μm. However, for
304both DDS, the energy-dispersive X-ray analysis plots detected
305the presence of nitrogen from the CHC molecule on the
306spotted surface.
Table 1. Loading of CHC in the DDS
DDS CHC (mmol)a CHC (mmol)b yield (%)c
CHC@A1:10 0.260 0.198 76.2
CHC@A2:10 0.520 0.377 72.5
CHC@A5:10 1.300 0.876 67.4
CHC@Y1:10 0.259 0.226 87.3
CHC@Y2:10 0.517 0.438 84.8
CHC@Y5:10 1.310 1.081 82.5
aInitial CHC amount in the solution. bCHC loading in zeolite.
cEncapsulation eﬃciency of CHC in zeolites.
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307 The integrity of the CHC in zeolites was conﬁrmed by the
308 analytical data of carbon and nitrogen content obtained by
309 elemental analysis. The theoretical C/N ratio for CHC is 8.6
310 (63.49% to C and 7.40% to N). All samples based in diﬀerent
311 zeolites present a similar C/N ratio. For example, the guest C/
312 N ratio obtained for CHC@Y1:10 is 8.7 (1.66% to C and 0.19%
313 to N) and for CHC@A1:10 it is 8.3 (1.49% to C and 0.18% to
314 N), indicating the presence of the molecular drug structure in
315 the zeolite.
316 Evidence for the interaction between CHC and the zeolites is
317 forthcoming from spectroscopic data. The 13C CP/MAS NMR
318spectra of CHC, CHC@Y1:10, and CHC@A1:10 are shown in
319 f2Figure 2.
320The spectrum of CHC shows the characteristic peaks of the
321drug molecule, consistent with the assignment previously
322reported for similar compounds.
49 Peaks in the same spectral
323regions appear in both encapsulated zeolites, indicating the
324presence of CHC in the pores of the materials. The diﬀerences
325between the spectra of the pure and the zeolite-encapsulated
326samples are attributed to drug interactions with and/or
327conformational changes induced by the presence of Na+ ions,
Figure 1. Scanning electron microscopy (SEM) images of zeolites and DDS herein studied. Scale bars represent 5 μm: NaY (a), NaA (b), CHC@
Y1:10 (c), and CHC@A1:10 (d) with the same resolution (×5000).
Figure 2. 13C CP/MAS NMR spectra of CHC, CHC@Y1:10, and CHC@A1:10.
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328 water molecules, and/or the zeolite framework. These
329 observations are consistent with the FTIR results (see below).
330 The eﬀect of the solvent on the preparation of the samples
331 was also studied by 27Al MAS NMR. The 27Al MAS NMR
332 spectra of the parent zeolites, CHC@zeolites1:10 and acetone@
f3 333 zeolites, are shown in Figure 3.
334 All samples contain four-coordinated aluminum framework
335 species [Al(OSi)4], as revealed by the peaks at 60.9 ppm for Y
336 and 53.9 ppm for LTA samples. No shift or broadening of the
337
27Al peaks were observed upon introduction of the solvent or
338upon drug-molecule encapsulation, including no changes in the
339octahedral-coordinated region (even if a faint broad peak at ca.
3405 ppm, presumably from the impurity, is observed for all LTA
341samples), indicating that the experimental procedures do not
342provoke damages in the structure in agreement with XRD and
343SEM analyses. The same behavior was observed in the 23Na
344solid-state MAS NMR spectra. The faint and sharp 27Al
345resonance at 78.5 observed in the spectra of the LTA samples
346(Figure 3b) is assigned to the unknown impurity contaminating
347the parent sample and also revealed by XRD.
348The presence of the drug and its interactions in both zeolites
349are also screened by Fourier transformed infrared spectroscopy
350 f4(FTIR). Figure 4 shows the infrared spectra of NaY (A) and
351NaA (B) for CHC (a), zeolites (b), and CHC@zeolite1:10 (c).
352The FTIR spectrum of CHC (Figure 4a) shows the presence
353of ν(CN) at 2230 cm−1, ν(CO) at 1678 cm−1, and the
354vibrational bands characteristic of the CC and CH groups
355around 1550 and 1150 cm−1. For the prepared DDS, the FTIR
356spectra of zeolites and the samples are dominated by the strong
357bands assigned to the vibration of the zeolite structure. The
358presence of physisorbed water is detected by the ν(OH)
359stretching vibration at 3410 cm−1 and the ν(OH)
360deformation band at 1635 cm−1. The bands corresponding to
361the lattice vibrations are observed in the spectral region
362between 1300 and 450 cm−1.47,48
Figure 3. 27Al MAS NMR spectra of parent Y (a) and LTA (b) zeolites and in the presence of solvents: acetone@zeolite and CHC@zeolite1:10..
Figure 4. FTIR spectra of NaY (A) and NaA (B) for CHC (a),
zeolites (b), and CHC@zeolite1:10 (c).
Table 2. Final Assay Concentrations of CHC in the Diﬀerent
DDS
DDS 1.00
mg/mL
(mM)
DDS 0.25
mg/mL
(mM)
DDS 0.10
mg/mL
(mM)
DDS 0.05
mg/mL
(mM)
CHC@A
1:10
0.198 0.050 0.020 0.010
CHC@A
2:10
0.377 0.094 0.038 0.019
CHC@A
5:10
0.876 0.219 0.088 0.044
CHC@Y
1:10
0.226 0.057 0.023 0.011
CHC@Y
2:10
0.435 0.109 0.044 0.022
CHC@Y
5:10
1.081 0.270 0.108 0.054
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363 In addition to these strong bands caused by the host zeolite,
364 the FTIR spectra for CHC@zeolite1:10 (Figure 4c) exhibits
365 bands in the regions 2500−2000 cm−1 and 1600−1200 cm−1
366 where the zeolites do not absorb and they are attributed to the
367 presence of the encapsulated drug. The spectra of the
368 encapsulated as well as pure CHC showed similar bands. For
369 example, the spectrum of CHC@A1:10 shows bands from CHC
370 at 2216, 1506, 1419, and 1311 cm−1. No shift or broadening in
371 the principal zeolite vibrational bands occur upon inclusion of
372 the drug, further substantiating that the zeolite framework
373 remains unchanged. Although the characteristic CHC FTIR
374 vibrational bands in the CHC@zeolite spectra are weak, they
375 provide evidence for the presence of drug in the zeolite. Due to
376 overlap with the strong bands arising from the zeolite
377 framework, it is not possible to draw any further conclusions
378 from these data. NMR spectroscopy is, thus, much more
379 sensitive to molecule structural changes than is FTIR.
380 Drug Bioactivity Studies. Working DDS concentrations
381 (0.05, 0.10, and 0.25 mg/mL) were obtained by diluting a stock
382 suspension (1.00 mg/mL) in culture medium (RPMI1640).
383 For better homogenization, all suspensions were submitted to
384ultrasonic dispersion for 2 min prior to use. The concentrations
385of zeolite suspensions used in this work and the corresponding
386 t2CHC ﬁnal assay concentrations are presented in Table 2.
387To be considered as suitable DDS, zeolites themselves
388should present small or no eﬀect on cell viability. The
389cytotoxicity of the starting zeolites was investigated in the
390 f5HCT-15 cell line. Figure 5 shows the eﬀect of increasing
391amounts of both zeolites NaY and NaA on the viability of
392HCT-15 cells, determined by the SRB assay.
393The two zeolites used gave similar results. The diﬀerences
394between controls (without zeolite) and the range of zeolite
395concentrations are insigniﬁcant, showing in this way that both
396zeolites are nontoxic to the cells for the selected period of
397incubation. To verify whether the encapsulation of CHC into
398zeolites potentiates the eﬀect of this monocarboxylate trans-
399porter (MCT) inhibitor, the eﬀect of zeolite NaA and NaY
400loaded with diﬀerent amounts of CHC was tested in HCT-15
401cell viability with increasing concentrations of the CHC@
402zeolite systems (0.05−0.25 mg/mL). Compared to NaY alone
403(control), there is an evident reduction in cell viability, from
Figure 5. Eﬀect of NaY and NaA zeolites on HCT-15 colon carcinoma cell viability. The HCT-15 cell line was incubated with the diﬀerent zeolite
concentrations for 24 h. Cell viability was measured by SRB assay. Values are means ± SD of three independent experiments, each performed in
triplicate. p < 0.05, compared to the control bar (cells without zeolite).
Figure 6. Eﬀect of NaY zeolite and CHC@NaY systems on HCT-15 colon carcinoma cell viability. The HCT-15 cell line was incubated with NaY
and diﬀerent DDS concentrations for 24 h. Cell viability was measured by SRB assay. Values are means ± SD of three independent experiments, each
performed in triplicate. The asterisk indicates p < 0.05, compared to the control bar (NaY).
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f6 404 74% to 58%, with increasing concentrations of CHC in the
f6 405 zeolite system (Figure 6).
406 The cytotoxic eﬀect of DDS with NaY was more pronounced
407 for higher concentrations of CHC; however, the eﬀect appears
408 not to be directly proportional to the concentrations of the
409 zeolite suspensions. For CHC@NaA, the cytotoxicity was not
410 as high as for NaY zeolite, a reduction of cell viability from 82%
411 to 66% was obtained when comparing with cells treated with
f7 412 the starting zeolite (Figure 7).
f8 413 Figure 8 shows the eﬀects on cell viability obtained when
414 treating HCT-15 cells with the nonencapsulated CHC.
415 Working concentrations (1.5, 3.0, 6.0, 12.0, and 20.0 mM)
416 were obtained by diluting the stock solution (2.9 M) in culture
417 medium (RPMI 1640). It is possible to observe a dose-
418 dependent decrease in cell viability, being the IC30 and IC50
419 values of 6.43 mM and 10.26 mM, respectively.
420 By comparing the results obtained when treating the HCT-
421 15 cells with the nonencapsulated CHC with the ones of
422 encapsulated CHC, there is an obvious potentiation of the
423 eﬀect of the drug. A 6.43 mM concentration of the
424nonencapsulated drug is necessary for a 30% of inhibition of
425cell viability (IC30) (Figure 8). In contrast, with the
426encapsulated drug, for the same magnitude of inhibition and
427for the 0.05 mg/mL of concentration zeolite suspension of the
428diﬀerent system of CHC@Y, there is an increase in eﬃciency of
429the drug between 119- and 585-fold, corresponding to CHC
430assay concentrations of 0.054 and 0.011 mM, respectively
431(Table 2).
432The studies for CHC@A showed a lower eﬀect on in-cell
433viability when compared with NaY. For 30% inhibition of cell
434viability, using 0.05 mg/mL of concentration zeolite suspension
435of the CHC@A system, there is an eﬃciency of the drug eﬀect
436between 29- and 146-fold, corresponding to CHC assay
437concentrations of 0.220 and 0.044 mM, respectively (Table 2).
438NaY DDS was more eﬀective than NaA DDS due to the
439more open structure of the zeolite Y, in which CHC could
440freely diﬀuse to the outside of the structure toward the cells.
441However, for higher concentrations of the system or parent
442zeolite (above 0.25 mg/mL), the cell viability begins to be
443aﬀected, likely due to the compromise of cell-nutrient exchange
444with the culture media.
445By encapsulating CHC into zeolites, we increased signiﬁ-
446cantly the eﬃciency of this drug, which could be related to
447CHC solubility. Since it is a hydrophobic molecule, it is diﬃcult
448to obtain a homogeneous solution with CHC. Thus, we believe
449that similarly to other systems,
50−53 the zeolite DDSs allow the
450slow release of CHC, increasing the bioavailability of the drug,
451and thus explaining this increase in potency. Another
452hypothesis, which would explain the high increase in potency,
453could be the promotion of CHC entry into the cell. It is
454described that CHC could inhibit the entry of pyruvate into the
455mitochondria, compromising the normal respiration of cells,
54
456at much lower concentrations. Thus, this high potency could be
457the combined result of both the increase in CHC bioavailability
458and the promotion of CHC entry into the cell by the DDS.
Figure 7. Eﬀect of NaA zeolite and CHC@NaA systems on HCT-15 colon carcinoma cell viability. The HCT-15 cell line was incubated with NaA
and diﬀerent DDS concentrations for 24 h. Cell viability was measured by SRB assay. Values are means ± SD of three independent experiments, each
performed in triplicate. Teh asterisk indicates p < 0.05, compared to the control bar (NaA).
Figure 8. Eﬀect of CHC on HCT-15 colon carcinoma cell viability.
The HCT-15 cell line was incubated with increasing concentrations of
CHC for 24 h. Cell viability was measured by SRB assay. Values are
means ± SD of three independent experiments, each performed in
triplicate. The asterisk indicates p < 0.05, compared to the control bar
(vehicle, no CHC).
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459 ■ CONCLUSIONS
460 The studies on the zeolites discussed here demonstrate that
461 these structures can be used eﬀectively for sustained release
462 applications. Two diﬀerent structures of zeolites, faujasite
463 (FAU) and Linde type A (LTA), were prepared and
464 characterized to assess their ability to encapsulate and release
465 the experimental anticancer drug CHC. The eﬀect of the
466 zeolites and CHC@zeolite DDS on the HCT-15 human colon
467 carcinoma cell line viability was evaluated. Both zeolites alone
468 revealed no toxicity to HCT-15 cancer cells. Importantly,
469 CHC@zeolite led to an inhibition of cell viability up to 585-
470 fold when compared to the nonencapsulated drug. These
471 results indicate the potential of the zeolites for drug loading and
472 delivery to cancer cells.
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